Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents
Sequenom, Inc. announced that it has secured exclusive rights to fundamental patent rights for digital PCR technologies and methods through a licensing agreement with Genomic Nanosystems, LLC, a wholly owned subsidiary of the Cytonix Corporation. The exclusively licensed rights include United States Patent Nos. 6,143,496 and 6,391,559 and pending applications. The license provides Sequenom with the exclusive right to use digital PCR methods on any platform for noninvasive prenatal diagnostics and analysis for any sample (for example, fetal cells, amniocentesis fluids, plasma, urine, etc.). Sequenom also secured the exclusive right to use digital PCR methods in conjunction with mass spectrometry for any commercial, diagnostic or research purpose, excluding second generation sequencing. Financial terms were not disclosed.
"Sequenom's extensive intellectual property position in noninvasive prenatal diagnostic testing for the assessment of fetal Down syndrome and other fetal genetic conditions is enhanced by this partnership, enabling us to develop even more highly sensitive tests on our MassARRAY(R) system, as well as other platforms of our choice in our fields of use," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "We are particularly pleased to be chosen as an exclusive partner by Genomic Nanosystems. These exclusive rights, as well as the licensing agreement we announced last week, further strengthen the proprietary foundation upon which we will continue product development and commercialization in our SEQureDx(TM) diagnostics business. Furthermore, Sequenom intends to develop a MassARRAY platform-based digital PCR solution for our genomic analysis business and for cancer research and diagnostics."
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!